Please assess the completion status of the following clinical trial:

Trial Title: Trigeminal Nerve Stimulation for ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male and female children ages 8 to 12 years with DSM-5 ADHD, any current presentation, as determined by KSADS and clinical interview~* minimum scores of 12 on both the inattentive and hyperactive/impulsive subscales of the baseline ADHD-RS~* CGI-S score at baseline ≥ 4~* no current medication with CNS effects~* parents able and willing to monitor proper use of the stimulation device and complete all required rating scales~* estimated Full Scale IQ ≥ 85 based on WASI subtests~* parent and participant able to complete rating scales and other measures in English~* able to cooperate during EEG~Exclusion Criteria:~* impaired functioning to a degree that requires immediate initiation of ADHD medication in the opinion of the parents and/or investigator~* current diagnosis of autism spectrum disorder or major depression~* history of lifetime psychosis, mania, seizure disorder or head injury with loss of consciousness~* baseline suicidality

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Active eTNS (Type: EXPERIMENTAL): Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Positive responders will be invited to participate in a 12-month open extension.
- Sham eTNS (Type: SHAM_COMPARATOR): Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Following double-blind phase, interested participants randomized to sham have an option for a 4-week open TNS trial. Positive responders will be invited to participate in a 12-month open extension.

Based on this trial design, predict the completion outcome and termination type (if applicable).